Latest Protein kinase inhibitor Stories
For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.
The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass.,
RIDGEFIELD, Conn., July 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex,
-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29,
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.